Why is this study important?

• Elevated Lipoprotein(a) [Lp(a)] identifies substantial residual cardiovascular risk, even in patients enrolled in rigorously conducted NIH randomized trials.
• Lp(a) levels >175 mg/dL confer a risk of major adverse cardiovascular events (MACE) comparable in magnitude to tobacco use, underscoring its importance as a clinically actionable risk marker.

What question was this study supposed to answer?

Residual cardiovascular risk remains a persistent challenge despite advances in guideline-directed medical therapy. Lipoprotein(a) has emerged as a genetically determined risk factor, but its prognostic significance in well-characterized, prospectively followed clinical trial populations has been incompletely defined. This study sought to determine whether elevated Lp(a) independently predicts major adverse cardiovascular events by leveraging biorepository samples from multiple NIH-sponsored randomized trials, addressing a key gap in risk stratification.

What did the study show?

In this meta-analysis of three NIH randomized trials, investigators used prospectively collected biorepository samples to evaluate the relationship between Lp(a) levels and clinical outcomes. Elevated Lp(a) >175 mg/dL was independently associated with a significantly increased risk of MACE, even after adjustment for traditional cardiovascular risk factors. The magnitude of risk associated with high Lp(a) approached that of active tobacco use, highlighting its clinical relevance. These findings reinforce Lp(a) as a major contributor to residual cardiovascular risk and support broader screening and the development of targeted therapies to address this unmet need.